GlassScriptPhysician profile
Scott S Bowers
NPI 1609866763
$2,109.74
in general payments reported to CMS, 2019-2025
32 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $116 · 2021: $648 · 2022: $462 · 2023: $156 · 2024: $92.32 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.00 | 2019-2022 | |
| Coopersurgical, INC. | $239.88 | 2019-2023 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $145.25 | 2021-2025 | |
| Exeltis, USA INC. | $143.68 | 2020-2025 | Slynd |
| Aspira Women'S Health INC | $143.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.23 | 2019-2025 | |
| Hologic Sales and Service, LLC | $80.35 | 2019-2024 | Myosure Tissue Removal Device, Acessa Provu System, Coolseal Generator |
| Millicent US INC | $77.78 | 2025 | Femlyv, Intrarosa |
| Therapeuticsmd, INC. | $73.86 | 2021-2022 | |
| Biogen, INC. | $71.53 | 2025 | Zurzuvae |
| Alydia Health | $70.56 | 2021 | |
| Astellas Pharma US INC | $62.93 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $60.45 | 2020-2022 | |
| Medicem INC. | $57.87 | 2021-2023 | |
| Evofem Biosciences, INC. | $55.54 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $54.27 | 2021-2023 | |
| Myovant Sciences INC. | $52.22 | 2021-2022 | |
| Avion Pharmaceuticals | $39.43 | 2019-2022 | |
| Minerva Surgical, INC | $26.68 | 2019 | |
| Agile Therapeutics, INC. | $24.01 | 2021 | |
| Channel Medsystems, INC. | $22.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.94 | 2022 | |
| Amag Pharmaceuticals, INC. | $19.11 | 2019 | |
| Abbott Laboratories | $18.03 | 2024 | Proclaim |
| Axsome Therapeutics, INC. | $17.27 | 2025 | Auvelity |
| Virtus Pharmaceuticals LLC | $15.94 | 2021 | |
| Shield Therapeutics INC | $15.52 | 2023 | Accrufer |
| Sage Therapeutics, LLC | $14.32 | 2021 | |
| Novo Nordisk INC | $13.72 | 2023 | Saxenda, Wegovy |
| Duchesnay USA Incorporated | $13.19 | 2019 | |
| Meditrina | $11.71 | 2022 | |
| Organon LLC | $8.31 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.